PMID: 16625825Apr 22, 2006Paper

Anti-CD3 antibody MacroGenics Inc

Current Opinion in Investigational Drugs
William M Brown

Abstract

A non-FcR-binding anti-CD3 monoclonal antibody, hOKT3gamma1 (Ala-Ala), originally developed by Columbia University, is being developed by MacroGenics for the potential treatment of type 1 diabetes and autoimmune diseases. Phase I/II trials in patients with diabetes have been completed, and a phase II clinical trial in psoriatic arthritis was initiated in October 2005. A Phase II trial that will evaluate a multi-course study of the drug in patients with new-onset diabetes began in March 2006. MacroGenics is currently seeking to outlicense the project to a strategic partner.

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

© 2022 Meta ULC. All rights reserved